1.Surgical treatment for perihilar cholangiocarcinoma:a single-center experience.
Wan Ying DENG ; Xiang De SHI ; Yan Fang YE ; Qi Bin TANG ; Hao Ming LIN ; Xian Hao YU ; Chao LIU
Chinese Journal of Surgery 2023;61(5):381-388
Objective: To investigate surgical strategies and the corresponding benefits for patients with perihilar cholangiocarcinoma(pCCA). Methods: A total of 81 patients with pCCA who underwent radical excision in the Department of Biliary and Pancreatic Surgery of Sun Yat-Sen Memorial Hospital between January 2014 and December 2021 were retrospectively collected.The cohort consisted of 50 male and 31 female patients,with an age of (62.5±11.5)years(range:26 to 83 years).Seventy-five cases were diagnosed with jaundice,60 of whom received preoperative biliary drainage,while 20 patients received portal vein embolization.Their serum bilirubin level within one week before the operation(M(IQR)) was 44.3 (41.9) μmol/L(range:8.0 to 344.2 μmol/L).Preoperative imaging examinations were performed to evaluate the Bismuth-Corlette type of pCCA,showing 3,6,21,27,and 24 cases of Bismuth-Corlette type Ⅰ,Ⅱ,Ⅲa,Ⅲb,and Ⅳ,respectively.The primary outcome was overall survival (OS),and the secondary outcomes were relapse-free survival (RFS),90-day postoperative morbidity and 90-day postoperative mortality.OS and RFS were estimated using the Kaplan-Meier method and compared by the Log-rank test.Significant prognostic factors were determined using univariate and multivariable Cox proportional hazard regression analyses. Results: In the cohort of 81 pCCA patients,67 cases(82.7%) underwent major hepatectomy while 3 cases received major hepatectomy combined with pancreaticoduodenectomy.Thirty-four patients underwent hepatectomy combined with vascular resection and reconstruction(18 cases of portal vein resection and reconstruction alone;9 cases of hepatic artery resection and reconstruction alone;7 cases of combination of portal vein and hepatic artery resection and reconstruction).Margin negative(R0 excision) were achieved in 53.1%(43/81) of these patients.The operation duration was (627±136)minutes(range:565 to 940 minutes),and the intraoperative blood loss was 400(455)ml(range:200 to 2 800 ml).The 90-day postoperative mortality was 3.7%(3/81).Grade 3-4 postoperative morbidity was 23.4% (19/81) according to the Clavien-Dindo classification of surgical complications.Up to the last follow-up at September 2022,the follow-up time was 34.0(24.2)months (range:0.4 to 103.6 months).Three patients who died within 90 days after surgery were excluded from the survival analysis.The median OS was 36.10 months (95%CI:18.23 to 42.97 months) and the 1-,3-and 5-year OS rates were 85.3%,46.8% and 27.3%,respectively.The median OS of 41 patients with negative margins was 47.83 months(95%CI:36.90 to 58.80 months) and that of 37 patients with positive margins was 20.47 months(95%CI:10.52 to 30.58 months).The median RFS of 70 patients with R0 and R1 resection was 24.50 months(95%CI:12.15 to 31.85 months)and the 1-,3-and 5-year RFS rates were 65.2%,45.7% and 29.9%,respectively.The median RFS of 41 patients with R0 resection was 38.57 months(95%CI:21.50 to 55.63 months) and that of 29 patients with R1 resection was 10.83 months(95%CI:2.82 to 19.86 months). Conclusions: The primary therapy for pCCA is radical surgical resection.A precise preoperative evaluation and sufficient preparation can reduce postoperative morbidity.Surgical treatment can achieve a better survival outcome by increasing the radical resection rate.
2.Mechanism of Linggui Zhugantang in Repairing Blood-brain Barrier Injury of Alzheimer's Disease
Zi-wei WANG ; Xi-bin ZHOU ; Ju DENG ; Yun LING ; Chun-xiang ZHOU
Chinese Journal of Experimental Traditional Medical Formulae 2022;28(1):16-23
ObjectiveTo observe the effect of Linggui Zhugantang (LG) on the blood-brain barrier (BBB) model of Alzheimer's disease (AD) in vitro and to explore the mechanism of LG in repairing the BBB injury in AD. MethodA total of 50 male SPF rats were randomized into five groups: high-dose (4.8 g·kg-1), medium-dose (2.4 g·kg-1), and low-dose (1.2 g·kg-1) LG groups, western medicine (0.5 g·kg-1 donepezil hydrochloride) group, and normal group (normal saline of equivalent volume). They received (ig) corresponding drugs twice a day for 7 d. Drug-containing serum was respectively collected from the abdominal aorta 1 h after the last administration. The BBB injury of AD in vitro was induced with the cell co-culture method, and 6 groups were designed: normal group, model group, high-, medium-, and low-dose LG groups, and western medicine group. The model group was added with 100 μL amyloid β1-42 (Aβ1-42, final concentration: 5 μmol·L-1), and high-dose, medium-dose, and low-dose LG groups and the western medicine group were added with corresponding 10% drug-containing serum in addition to the 100 μL Aβ1-42 (final concentration: 5 μmol·L-1). Cell survival rate was detected by methyl thiazolyl tetrazolium (MTT) assay, expression of BBB-related skeleton proteins (claudin-5, ZO-1, occludin), matrix metalloproteinase-2 (MMP-2), and matrix metalloproteinase-9 (MMP-9) by Western blot, and content of inflammatory factors interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) by enzyme-linked immunosorbent assay (ELISA). BBB Aβ transporter low-density lipoprotein receptor-related protein 1 (LRP-1) and advanced glycation end product receptor (RAGE) at different time points in high-dose, medium-dose, and low-dose LG groups were determined by Real-time PCR and Western blot. ResultCell survival rate of the model group was lower than that of the normal group (P<0.05) and the survival rates of the western medicine group and high-dose LG group was higher than that in the model group (P<0.05). The skeleton proteins were down-regulated and MMP-2 and MMP-9 were up-regulated in the model group compared with those in the normal group (P<0.05). The expression of skeleton proteins was higher (P<0.05) and that of MMP-2 and MMP-9 was lower (P<0.05) in the western medicine group and high-dose LG group than in the model group. Compared with the model group, only the medium-dose LG group showed the up-regulation (P<0.05) of claudin-5 (P<0.05) and the decrease (P<0.05) of MMP-2. IL-1β, IL-6, and TNF-α in the model group were up-regulated (P<0.05) compared with those in the normal group, and those inflammatory factors in the western medicine group and high-dose and medium-dose LG groups were lower (P<0.05) than those in the model group. LRP-1 expression was up-regulated and RAGE expression was down-regulated at 3 h compared with those at 0 h (P<0.05), while the expression of the two became stable at 6, 12, 24, 36 h. At 3 h, LRP-1 expression was down-regulated and RAGE expression was up-regulated in model group compared with those in the normal group at 3 h (P<0.05). Moreover, the LRP-1 content was higher and RAGE content was lower in the western medicine group and high-dose LG group than in the model group. ConclusionLG can repair the BBB injury in vitro by inhibiting the expression of inflammatory factors and MMP-2, MMP-9, promoting the expression of skeletal proteins, and regulating the balance of transporters.
3.Effects of Human Immunodeficiency Virus-positive Mothers Receiving Antiretroviral Therapy to Prevent Mother-to-child Transmission on the Growth and Development of 18-month-old Children in Lingshan County of Guangxi.
Xian-Min GE ; Mei LIN ; Jin-Mei CHEN ; Jin-Hui ZHU ; Guang-Hua LAN ; Yu YAN ; Huan-Huan CHEN ; Liu-Hong LUO ; Shan-Shan LI ; Bin LI ; Guang-Hua HUANG ; Jia-Wei LI ; Yue-Qin DENG ; Ping-Jing WEN ; Yu-Man HUANG ; Qiu-Ying ZHU ; Qin MENG ; Shuai-Feng LIU ; Xiu-Ling WU ; Jing-Hua HUANG ; Hua-Xiang LU
Acta Academiae Medicinae Sinicae 2021;43(5):743-748
Objective To evaluate the effects of antiretroviral therapy(ART)for the prevention of mother-to-child transmission(PMTCT)of acquired immune deficiency syndrome(AIDS)on the growth and development of 18-month-old children born by human immunodeficiency virus(HIV)-positive pregnant women in Lingshan County,Guangxi Zhuang Autonomous Region,and provide scientific evidence for improving the ART medication plan for PMTCT.Methods Lingshan County,ranking the first in the HIV-epidemic counties of Guangxi,was selected as the research site.According to the design of retrospective case-control study,we assigned all the subjects into the case group and the control group:(1)The case group included the HIV-positive pregnant women who had received ART for PMTCT and their HIV-negative infants in Lingshan County from 2010 to 2017.The historical cards and PMTCT data of them were collected from the national PMTCT database.(2)The control group included the healthy pregnant women and their healthy babies born in the Lingshan Maternity and Infant Hospital in 2017,and the children's growth and development data were collected.The stunted growth in children was defined as at least one of the three main indicators of body height,body weight,and head circumference below the normal range.Results The number of HIV-positive mothers and their infants in the case group was 391 and 368,respectively,and 87.21%(341/391)and 95.38%(351/368)of mothers and infants respectively received ART medication.The HIV positive rate,mortality rate,and mother-to-child transmission rate of 18-month-old children were 1.36%(5/368),4.35%(16/368),and 2.01%(5/249),respectively.The incidence of stunted growth of 18-month-old children in the case group and the control group was 42.12%(155/368)and 23.06%(101/438),respectively,with significant difference(
Case-Control Studies
;
China/epidemiology*
;
Female
;
Growth and Development
;
HIV
;
HIV Infections/prevention & control*
;
Humans
;
Infant
;
Infectious Disease Transmission, Vertical/prevention & control*
;
Mothers
;
Pregnancy
;
Pregnancy Complications, Infectious/drug therapy*
;
Retrospective Studies
4.Case-control study on the Endobutton plate and clavicular hook plate for the treatment of acromioclavicular joint dislocation.
Xiao-Dong HAN ; Bin DENG ; Xiang-Bo MENG ; Xian-Zhong JI ; Xian-Qing MENG
China Journal of Orthopaedics and Traumatology 2021;34(12):1152-1157
OBJECTIVE:
To study the clinical efficacy and complications of Endobutton titanium plate and clavicle hook plate in the treatment of acromioclavicular dislocation.
METHODS:
Total 48 patients with Rockwood Ⅲ to Ⅴ acromioclavicular joint dislocation from March 2015 to May 2019 were retrospectively divided into two groups according to different surgical methods. Among the patients, 23 patients were treated with Endobutton loop titanium plate fixation (observation group), including 15 males and 8 females, ranging in age from 23 to 59 years old, with an average of(36.2±8.1) years old;Rockwood type Ⅲ in 6 cases, type Ⅳ in 11 cases and type Ⅴ in 6 cases. Twenty-five patients were treated with clavicular hook plate(control group), including 17 males and 8 females, ranging in age from 22 to 54 years old, with an average of (34.7±6.4) years old; Rockwood type Ⅲ in 6 cases, type Ⅳ in 14 cases and type Ⅴ in 5 cases. The operation time, intraoperative bleeding, hospitalization time, visual analogue scale (VAS) of pain, Constant-Murley score of shoulder function and postoperative complications were compared between the two groups.
RESULTS:
All the patients were followed up, and the duration ranged from 24 to 51 months, with a mean of (30.5±6.5) months. The amountof bleeding and hospitalization time in the observation group were (71.9±4.0) ml and(8.2±1.6) d respectively;and those in the control group were (97.6±13.4) ml and (12.8±1.2) d respectively. There was significant difference between the two groups (
CONCLUSION
Compared with clavicular hook plate internal fixation in the treatment of acromioclavicular joint dislocation, Endobutton loop titanium plate internal fixation technology has the advantages of less surgical bleeding, shorter hospitalization time, less postoperative pain, good recovery of shoulder joint function and less complications.
Acromioclavicular Joint/surgery*
;
Adult
;
Bone Plates
;
Case-Control Studies
;
Female
;
Humans
;
Joint Dislocations/surgery*
;
Male
;
Middle Aged
;
Retrospective Studies
;
Treatment Outcome
;
Young Adult
5.Implications, spiritual characteristics and practical significance of Chinese schistosomiasis control culture
Wei-Cheng DENG ; Yue-Sheng LI ; Xiang-Hui CHENG ; Guang-Hui REN ; Hong-Bin HE ; Yi-Biao ZHOU ; Yue-Yun ZHANG ; Ben-Jiao HU ; Han-Qiu LIU ; Shi-Kui LU ; Sheng-Ming LI ; Xiao-Nong ZHOU
Chinese Journal of Schistosomiasis Control 2020;32(3):222-224
The culture of schistosomiasis control is specific in the history of Chinese culture. Broadly speaking, the culture of schistosomiasis control is a summary of specific social mood, social consciousness and material culture created by Chinese populations during the progress of schistosomiasis control since the founding of the People’s Republic of China. Narrowly speaking, the culture of schistosomiasis control is the spiritual culture that is jointly created and nurtured by schistosomiasis control workers since the founding of the People’s Republic of China. The spiritual features of Chinese schistosomiasis control culture are characterized by the patriotism and care about the people, the matter-to-fact attitude, the pioneering and enterprising spirit, and the spirit of sacrifice and dedication. The ultimate goal of the research on the culture of schistosomiasis control is to facilitate the achievement of the strategic goal of Healthy China 2030 as scheduled, accelerate the progress towards elimination of schistosomiasis, and to promote the sustainable development of schistosomiasis control in China.
6.Challenges and countermeasures of schistosomiasis control in Hunan Province in the new era
Sheng-Ming LI ; Wei-Cheng DENG ; Xiang-Hui CHENG ; Hong-Bin HE ; Yi-Biao ZHOU ; Jie ZHOU ; Ben-Jiao HU ; Han-Qiu LIU ; Shi-Kui LU ; Yue-Sheng LI ; Xiao-Nong ZHOU ; Guang-Hui REN
Chinese Journal of Schistosomiasis Control 2020;32(3):225-229
This paper describes the current epidemic characteristics and endemic status of schistosomiasis, analyzes the main challenges of schistosomiasis control and proposes the emphasis and interventions for future schistosomiasis control activities in Hunan Province, so as to provide insights into the elimination of schistosomiasis in Hunan Province.
7.Survey of the capacity building of the county-level schistosomiasis diagnosis network laboratory in Hunan Province
Meng XIA ; Xin-Ling YU ; Hong-Bin HE ; Guang-Ping LI ; Xiang WU ; Yi DENG ; Zhen-Hua LUO ; Jie ZHANG
Chinese Journal of Schistosomiasis Control 2020;32(3):311-313
Objective To examine the construction and operation of the schistosomiasis diagnostic network platform in Hunan Province, so as to provide insights into the improvements of the schistosomiasis diagnostic network laboratory system in the province. Methods According to the criteria and requirements for the construction of the county-level schistosomiasis diagnostic network laboratory in China, the establishment and operation of the laboratory were assessed using self-assessment and field review in national schistosomiasis surveillance sites of Hunan Province. Results A total of 41 county-level schistosomiasis diagnostic network laboratories were built in national schistosomiasis surveillance sites of Hunan Province, and 36 met the requirements for the construction of the national schistosomiasis diagnostic network laboratory in China, which were approved for inclusion in the province-level schistosomiasis diagnostic network laboratory. During the six inter-laboratory comparisons performed by the national schistosomiasis diagnostic reference center of China, full consistency was achieved by 3 county-level schistosomiasis diagnostic network laboratories in Hunan Province, and the coincidence rates for re-review of serological and pathogenic detection samples were 98.40% and 100%, respectively. Conclusion The county-level schistosomiasis diagnostic network laboratory system has been preliminarily built and under effective operation in Hunan Province; however, the building capability remains to be improved.
8.Asialoglycoprotein receptor 1 gene expression in peripheral blood monocytes associates with serum total cholesterol and low-density lipoprotein cholesterol levels.
Xiang ZHAO ; Bin TANG ; Zhi-Hua SHI ; Zi-Wei DENG ; Ye DENG ; Li-Ming TAN ; Shi-Long JIANG ; Yuan-Lu SHU ; Cheng-Feng QIU
Chinese Medical Journal 2020;133(12):1505-1506
9.Application of membrane induced by antibiotic loaded bone cement in skin grafting for tendon exposed wound healing.
Bin TAN ; Zhen-Lin WANG ; Deng-Bo LI ; Zhao XU ; Juan CHEN ; Shi-Zhi HOU ; Xiang WANG ; Wei WANG
China Journal of Orthopaedics and Traumatology 2020;33(6):564-566
OBJECTIVE:
To evaluate the effects of membrane induced by antibiotic-loaded bone cement in skin grafting for tendon exposed wound healing.
METHODS:
A total of 10 traumatic patients with tendon exposed wound were admitted to our department between February 2016 and December 2018, including 6 males and 4 females, with a mean age of 34.6 years old (ranged, 19 to 43 years old), and treatment duration ranged from 2 to 6 months. There were 7 cases of traffic accidents, 3 cases of mechanical belt injuries, including 8 cases of lower leg and foot wounds and 2 cases of hand back wounds. These tendons exposed wound were covered by antibiotic-loaded bone cement at the earlier stageto induce the formation of the biomembrane, and then skin grafting were performed on the induced membrane. The survival, appearance, texture, sensation of the skin grafting and healing condition of the wounds were studied.
RESULTS:
Among the 10 patients, skin graft survived well in 8 patients. Partial skin graft necrosis occurred in 2 patients and cured by dressing.
CONCLUSION
Using antibiotic bone cement to seal the wound to form induction membrane followed by skin grafting can effectively repair the tendon exposed wound, which has the characteristics of simple operation and less trauma.
Adult
;
Anti-Bacterial Agents
;
Bone Cements
;
Female
;
Humans
;
Male
;
Reconstructive Surgical Procedures
;
Skin Transplantation
;
Soft Tissue Injuries
;
Tendons
;
Treatment Outcome
;
Wound Healing
;
Young Adult
10.A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis.
Lin CAI ; Gen-Hui CHEN ; Qian-Jin LU ; Min ZHENG ; Yu-Zhen LI ; Jin CHEN ; Jie ZHENG ; Fu-Ren ZHANG ; Jian-Bin YU ; Sen YANG ; Fu-Qiu LI ; Sheng-Xiang XIAO ; Qiu-Ning SUN ; Jin-Hua XU ; Xing-Hua GAO ; Hong FANG ; Tian-Wen GAO ; Fei HAO ; Quan-Zhong LIU ; Ya-Ting TU ; Ruo-Yu LI ; Bao-Xi WANG ; Dan-Qi DENG ; Qing-Shan ZHENG ; Hong-Xia LIU ; Jian-Zhong ZHANG
Chinese Medical Journal 2020;133(24):2905-2909
BACKGROUND:
Benvitimod cream, a novel synthetic small molecule, was effective in treating mild-to-moderate plaque psoriasis. We conducted a phase III clinical trial to assess the efficacy and safety of benvitimod cream in patients with mild-to-moderate plaque psoriasis.
METHODS:
We randomly assigned 686 patients (2:1:1) to receive 1% benvitimod cream, 0.005% calcipotriol ointment or placebo twice a day for 12 weeks. The primary efficacy end points were the percentage of patients with a 75% or greater reduction from baseline in the psoriasis area and severity index (PASI 75) score and with a score of 0 or 1 in static physician's global assessment (sPGA) at week 12.
RESULTS:
The results showed that 50.4% of patients in the benvitimod group achieved PASI 75, which was significantly higher than that in the calcipotriol (38.5%, P < 0.05) and placebo (13.9%, P < 0.05) groups. The proportion of patients achieving an sPGA score 0 or 1 was 66.3% in the benvitimod group and 63.9% in the calcipotriol group, which were both significantly higher than that in the placebo group (34%, P < 0.05). In the long-term follow-up study, 50.8% of patients experienced recurrence. After retreatment with 1% benvitimod, 73.3% of patients achieved an sPGA score of 0 or 1 again at week 52. Adverse events included application site irritation, follicular papules, and contact dermatitis. No systemic adverse reactions were reported.
CONCLUSION:
During this 12-week study, benvitimod cream was demonstrated with high effectiveness and safety in patients with mild-to-moderate plaque psoriasis.
TRIAL REGISTRATION
Chinese Clinical Trial Registry (ChiCTR), ChiCTR-TRC-13003259; http://www.chictr.org.cn/showprojen.aspx?proj=6300.
Double-Blind Method
;
Follow-Up Studies
;
Humans
;
Ointments
;
Psoriasis/drug therapy*
;
Resorcinols
;
Severity of Illness Index
;
Stilbenes
;
Treatment Outcome

Result Analysis
Print
Save
E-mail